a Key Laboratory of Advanced Technology for Materials of Chinese Education Ministry, School of Materials Science and Engineering , Southwest Jiaotong University , Chengdu , China.
J Biomater Sci Polym Ed. 2017 Dec;28(17):2066-2081. doi: 10.1080/09205063.2017.1373989. Epub 2017 Sep 19.
Surface modification by immobilizing biomolecules has been widely proved to enhance biocompatibility of cardiovascular implanted devices. Here, we aimed at developing a multifunctional surface that not only provides good hemocompatibility but also functions well in capturing circulating endothelial progenitor cells (EPCs) in the blood flow to improve the surface endothelialization. In the present work, we preferred to chemically co-immobilize (Michael addition and Schiff base reaction) the anti-CD133 (EPC-specific antibody) and fucoidan (EPC-mobilization factor, which also contribute to better hemocompatibility) onto a polydopamine (PDA) film which is famous for its stability and endothelial cell (EC) compatibility. The quantality of anti-CD133 and other surface characterization (X-ray photoemission spectroscopy, atomic force microscopy and water contact angle measurement) demonstrated successful preparation of the CD133/fucoidan coating. The platelets adhesion/activation test suggested improved hemocompatibility of this bio-coating. The ex vivo experiment on New Zealand white rabbits showed that the anti-CD133/fucoidan coating had good ability on capture the circulating EPC. In addition, the quartz crystal microbalance-D indicated that the EPC behaviors, including adhesion, spreading and extracellular matrix re-molding, were related to the density of anti-CD133 in the coating. We hope this anti-CD133/fucoidan multi-functional coating may provide potential application on surface modification of cardiovascular biomaterials.
通过固定生物分子进行表面修饰已被广泛证明可增强心血管植入设备的生物相容性。在这里，我们旨在开发一种多功能表面，该表面不仅提供良好的血液相容性，而且还能很好地捕获血流中的循环内皮祖细胞（EPC），从而改善表面内皮化。在本工作中，我们倾向于通过化学共固定（迈克尔加成和席夫碱反应）将抗 CD133（EPC 特异性抗体）和褐藻糖胶（EPC 动员因子，也有助于更好的血液相容性）固定到聚多巴胺（PDA）膜上，PDA 膜以其稳定性和内皮细胞（EC）相容性而闻名。抗 CD133 的定量和其他表面特性（X 射线光电子能谱，原子力显微镜和水接触角测量）证明了 CD133/褐藻糖胶涂层的成功制备。血小板粘附/激活测试表明该生物涂层具有更好的血液相容性。新西兰白兔的离体实验表明，抗 CD133/褐藻糖胶涂层具有捕获循环 EPC 的良好能力。此外，石英晶体微天平-D 表明，EPC 的行为，包括粘附，铺展和细胞外基质重塑，与涂层中抗 CD133 的密度有关。我们希望这种抗 CD133/褐藻糖胶多功能涂层可为心血管生物材料的表面改性提供潜在的应用。
